Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00026182 · ClinicalTrials.gov registry record · Phase 2
Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
NCT00026182: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00026182 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 99 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00026182, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
Study Summary
Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Interleukin-12 may kill cancer cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Combining rituximab with interleukin-12 may kill more cancer cells. This randomized phase II trial is comparing how well giving rituximab together with two different schedules of interleukin-12 works in treating patients with B-cell non-Hodgkin lymphoma.
Interventions
- OTHER laboratory biomarker analysis
- OTHER questionnaire administration
- BIOLOGICAL rituximab
- PROCEDURE quality-of-life assessment
- BIOLOGICAL recombinant interleukin-12
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2001-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00026182
The ClinicalTrials.gov registry entry for NCT00026182 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00026182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00026182 about?
NCT00026182 is a clinical study titled "Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma". Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Interleukin-12 may kill cancer cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer ce...
What is the current status of trial NCT00026182?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2001-10.
What interventions are being tested in trial NCT00026182?
The interventions under investigation include: laboratory biomarker analysis (OTHER), questionnaire administration (OTHER), rituximab (BIOLOGICAL), quality-of-life assessment (PROCEDURE), recombinant interleukin-12 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00026182?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.